Zeta CD205 Antibody. Zeta’s recombinant mouse antibody recognizes CD205, a type I transmembrane glycoprotein and is a member of the C-type lectin receptor family. CD205 is robustly expressed and highly prevalent in a variety of solid malignancies including pancreatic, bladder, and triple-negative breast cancer compared with that in the corresponding normal tissues. Additionally, CD205 was shown frequently expressed in lymphomas, leukemias and multiple myeloma, and is currently being explored as a drug target for lymphoma and other cancers.
CD205 is a multi-lectin receptor that belongs to the MMR (macrophage mannose receptor) family of multidomain molecules. MMR family molecules mediate membrane receptor targeting endosomes or lysosomes rich in major histocompatibility complex class II (MHC II) products. Expressed in mature dendritic cells, CD205 contains an extracellular N-terminal cysteine-rich domain, a fibronectin type II domain, ten C-type carbohydrate recognition domains, a single transmembrane region, and a small cytoplasmic C-terminal domain containing a tyrosine at 1679. CD205 elicits either an agonistic or antagonistic effect on IL-4 function, which is demonstrated by the ability of CD205 to imitate IL-4-induced maturation of epithelium or to inhibit IL-4-induced proliferation of T cells respectively. CD205 cts as an endocytic receptor to direct captured antigens from the extracellular space to a specialized antigen-processing compartment causing reduced proliferation of B-lymphocytes.